Sarepta Therapeutics (SRPT) News Today $54.63 +3.60 (+7.05%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period F M Investments LLC Acquires Shares of 16,924 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)F M Investments LLC bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 16,924 shares of the biotechnoloApril 14 at 5:41 AM | marketbeat.comBank of Nova Scotia Sells 185,102 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Bank of Nova Scotia cut its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 73.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 67,666 shares of the biotechnology company's stock after selling 185April 14 at 5:13 AM | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $163.18 Consensus Price Target from AnalystsApril 14 at 2:53 AM | americanbankingnews.comWells Fargo & Company Initiates Coverage on Sarepta Therapeutics (NASDAQ:SRPT)April 14 at 1:45 AM | americanbankingnews.comMorgan Stanley Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $182.00April 14 at 1:45 AM | americanbankingnews.comMorgan Stanley Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $182.00Morgan Stanley lowered their price target on shares of Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating on the stock in a research report on Friday.April 13 at 11:51 AM | marketbeat.comWells Fargo & Company Begins Coverage on Sarepta Therapeutics (NASDAQ:SRPT)Wells Fargo & Company started coverage on Sarepta Therapeutics in a research note on Friday. They set an "overweight" rating and a $115.00 target price for the company.April 13 at 9:12 AM | marketbeat.comCapital Fund Management S.A. Has $21.13 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Capital Fund Management S.A. lowered its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 14.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 173,745 shares of the biotechnology company's stock afterApril 13 at 6:28 AM | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of "Moderate Buy" by BrokeragesShares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twenty-three brokerages that are currently covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating, seventeen havApril 13 at 1:06 AM | marketbeat.comSRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. ...April 12 at 11:39 AM | gurufocus.comSarepta Therapeutics Inc (SRPT) Under Investigation for Potential Securities Law Violations | ...April 12 at 11:39 AM | gurufocus.comSarepta Therapeutics Inc (SRPT) Under Investigation for Potential Securities Law Violations | ...April 12 at 11:18 AM | gurufocus.comSRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the FirmApril 12 at 11:01 AM | prnewswire.comZacks Research Analysts Decrease Earnings Estimates for SRPTSarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Zacks Research decreased their Q1 2026 EPS estimates for shares of Sarepta Therapeutics in a research note issued to investors on Tuesday, April 8th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will earn $April 12 at 8:49 AM | marketbeat.comZacks Research Has Negative Estimate for SRPT Q1 EarningsApril 12 at 2:27 AM | americanbankingnews.comWells Fargo Initiates Coverage of Sarepta Therapeutics (SRPT) with Overweight RecommendationApril 12 at 1:04 AM | msn.comSarepta initiated with an Overweight at Wells FargoApril 11 at 8:03 PM | markets.businessinsider.comSarepta Therapeutics (SRPT) Receives a Buy from Morgan StanleyApril 11 at 3:03 PM | markets.businessinsider.comEquities Analysts Set Expectations for SRPT Q1 EarningsSarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Zacks Research decreased their Q1 2027 earnings per share (EPS) estimates for shares of Sarepta Therapeutics in a report released on Tuesday, April 8th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will pApril 11 at 8:12 AM | marketbeat.comQ1 EPS Estimate for Sarepta Therapeutics Reduced by AnalystApril 11 at 2:07 AM | americanbankingnews.comSarepta Therapeutics (SRPT) Sees Price Target Reduction by Guggenheim | SRPT Stock NewsApril 10, 2025 | gurufocus.comFederated Hermes Inc. Sells 128,418 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Federated Hermes Inc. trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 25.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 380,418 shares of the biotechnoloApril 10, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Sets New 12-Month Low - Here's WhySarepta Therapeutics (NASDAQ:SRPT) Reaches New 1-Year Low - Here's What HappenedApril 9, 2025 | marketbeat.comNASDAQ: SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the FirmApril 9, 2025 | businesswire.comADAR1 Capital Management LLC Boosts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)ADAR1 Capital Management LLC boosted its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 463.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,002 shares of the biotecApril 9, 2025 | marketbeat.comAlliancebernstein L.P. Has $21.88 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Alliancebernstein L.P. trimmed its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 17.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 179,908 shares of the biotechnology coApril 9, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTApril 8, 2025 | prnewswire.comSarepta price target lowered to $184 from $215 at OppenheimerApril 8, 2025 | markets.businessinsider.comSarepta Therapeutics (SRPT) Receives a Hold from ScotiabankApril 8, 2025 | markets.businessinsider.com3 Reasons to Avoid SRPT and 1 Stock to Buy InsteadApril 8, 2025 | msn.comCan Solid Biosciences Challenge Sarepta in the DMD Market? (SRPT)Solid Biosciences' Duchenne muscular dystrophy (DMD) drug could provide superior outcomes compared to an already approved medication projected to make billions.April 8, 2025 | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Stake Lifted by Finepoint Capital LPFinepoint Capital LP grew its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 21.3% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 161,935 shares of the biotechnology company's stock after buying an additional 28,400 shares during tApril 8, 2025 | marketbeat.comSit Investment Associates Inc. Buys 8,038 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Sit Investment Associates Inc. raised its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 22.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 44,390 shares of the biotechnology company's sApril 8, 2025 | marketbeat.comGeode Capital Management LLC Purchases 9,999 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Geode Capital Management LLC raised its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 0.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,706,353 shares of the biotApril 8, 2025 | marketbeat.comLPL Financial LLC Has $6.50 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)LPL Financial LLC lifted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 12.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,438 shares of the biotechnology company's stocApril 8, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTApril 7, 2025 | globenewswire.com4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall StreetApril 7, 2025 | fool.comPositive Outlook for Sarepta Therapeutics Amid Favorable Trial Evaluations and Proactive Regulatory ResponseApril 7, 2025 | tipranks.comCalifornia Public Employees Retirement System Has $17.40 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)California Public Employees Retirement System lessened its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 4.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 143,12April 6, 2025 | marketbeat.comSei Investments Co. Has $2.91 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Sei Investments Co. increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 31.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,935 shares of the biotechnology company's stoApril 6, 2025 | marketbeat.comTraders Buy Large Volume of Sarepta Therapeutics Put Options (NASDAQ:SRPT)Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Stock investors purchased 6,583 put options on the company. This represents an increase of 246% compared to the average daily volume of 1,901 put options.April 5, 2025 | marketbeat.comNeedham & Company LLC Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $183.00Needham & Company LLC reduced their target price on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating on the stock in a research report on Thursday.April 5, 2025 | marketbeat.comSarepta Therapeutics (SRPT) Gets a Hold from RBC CapitalApril 5, 2025 | markets.businessinsider.comSarepta Therapeutics (NASDAQ:SRPT) Given New $183.00 Price Target at Needham & Company LLCApril 5, 2025 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Rating Increased to Neutral at HC WainwrightApril 5, 2025 | americanbankingnews.comSarepta Therapeutics Stock Falls as Some Trials Halted After Patient DeathApril 5, 2025 | msn.comSarepta Therapeutics Temporarily Halts Three Clinical Studies Of Elevidys: Retail Is Dull While Stock DropsApril 5, 2025 | msn.comSarepta, Roche seek to resume Elevidys trialsApril 4, 2025 | msn.comSarepta Therapeutics Provides Update on ELEVIDYSApril 4, 2025 | gurufocus.comSarepta Therapeutics Inc (SRPT) Updates on ELEVIDYS Gene Therapy TrialsApril 4, 2025 | gurufocus.com Remove Ads Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address SRPT Media Mentions By Week SRPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SRPT News Sentiment▼0.381.00▲Average Medical News Sentiment SRPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SRPT Articles This Week▼4513▲SRPT Articles Average Week Remove Ads Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Teva Pharmaceutical Industries News Today Intra-Cellular Therapies News Today Summit Therapeutics News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Moderna News Today Viatris News Today Qiagen News Today Ascendis Pharma A/S News Today Roivant Sciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SRPT) was last updated on 4/14/2025 by MarketBeat.com Staff From Our PartnersThe biggest story CNBC isn't talking about (yet)This Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredDeFi Coin on Verge of Breakout!Crypto’s down — but the fundamentals aren’t. Strategic investors are using this dip to scoop up undervalued...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
